Swedish drugmaker Fermenta reported a 1.23 billion kroner ($203.4 million) loss for 1991, compared with a loss of 599 million kroner the previous year. Part of the loss (some 502 million kroner) was attributed to its financial services subsidiary Independent, which was sold in March.
The sale of Independent, as well as the Italian Pierrel pharmaceutical unit last year, also contributed to the 50% revenue plunge, from 3.57 billion kroner in 1990 to just 1.77 billion kroner ($292.8 million) for 1991.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze